Evolus (EOLS) Assets Average (2018 - 2026)
Evolus (EOLS) posted Assets Average of $223.3 million for Q1 2026, little changed on a QoQ basis from $222.4 million in Q4 2025, and little changed year-over-year from $223.0 million in Q1 2025.
Evolus (EOLS) Assets Average (2018 - 2026) Analysis & Trends
Evolus' Assets Average history runs 9 years deep, the most recent figure standing at $223.3 million for Q1 2026.
- Quarterly Assets Average changed 0.13% year-over-year to $223.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $223.3 million (changed 0.13% YoY) and the FY2025 annual result came in at $229.2 million, up 8.75% from the prior year.
- Assets Average was $223.3 million for Q1 2026 at Evolus, roughly flat from $222.4 million in the prior quarter.
- Across five years, Assets Average topped out at $239.1 million in Q1 2022 and bottomed at $164.6 million in Q2 2023.
- A 5-year average of $208.0 million and a median of $221.1 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average retreated 29.26% — and 2024, when it soared 39.71%.
- Evolus' Assets Average stood at $185.4 million in 2022, then decreased by 3.7% to $178.5 million in 2023, then gained by 29.47% to $231.1 million in 2024, then decreased by 3.75% to $222.4 million in 2025, then grew by 0.37% to $223.3 million in 2026.
- Business Quant data shows EOLS's Assets Average at $223.3 million in Q1 2026, $222.4 million in Q4 2025, and $223.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.32 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 99.52 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.30 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 68.63 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.77 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.29 Bn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | 223.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 223.26 Mn |
| Dec 31, 2025 | 222.43 Mn |
| Sep 30, 2025 | 223.90 Mn |
| Jun 30, 2025 | 221.08 Mn |
| Mar 31, 2025 | 222.97 Mn |
| Dec 31, 2024 | 231.09 Mn |
| Sep 30, 2024 | 231.69 Mn |
| Jun 30, 2024 | 229.97 Mn |
| Mar 31, 2024 | 207.59 Mn |
| Dec 31, 2023 | 178.48 Mn |
| Sep 30, 2023 | 168.48 Mn |
| Jun 30, 2023 | 164.61 Mn |
| Mar 31, 2023 | 169.11 Mn |
| Dec 31, 2022 | 185.35 Mn |
| Sep 30, 2022 | 201.82 Mn |
| Jun 30, 2022 | 215.79 Mn |
| Mar 31, 2022 | 239.07 Mn |
| Dec 31, 2021 | 236.35 Mn |
| Sep 30, 2021 | 227.54 Mn |
| Jun 30, 2021 | 198.53 Mn |